Recent advances in treatment strategies for atopic dermatitis

Drugs

Volumn 64, Issue 23, 2004, Pages 2639-2666

  Roos, Thomas Christian ^a   Geuer, Stefan ^a   Roos, Sabine ^a   Brost, Harald ^b  

^a Interdisc Ther Ctr for Allergies   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALCLOMETASONE DIPROPIONATE; BETAMETHASONE BENZOATE; BETAMETHASONE VALERATE; CALCINEURIN INHIBITOR; CLIOQUINOL; CLOBETASONE BUTYRATE; CORTICOSTEROID; CRYSTAL VIOLET; DESONIDE; DESOXIMETASONE; DEXAMETHASONE; FLUDROXYCORTIDE; FLUMETASONE PIVALATE; FLUOCORTIN BUTYL; FLUOCORTOLONE; FLUPREDNIDENE ACETATE; FUCHSINE; HALCINONIDE; HYDROCORTISONE; HYDROCORTISONE 17 BUTYRATE 21 PROPIONATE; HYDROCORTISONE ACETATE; HYDROCORTISONE BUTYRATE; IMMUNOMODULATING AGENT; METHYLPREDNISOLONE ACEPONATE; PREDNICARBATE; PREDNISOLONE; RESORCINOL; SALICYLIC ACID; SDZ ASM 381; TACROLIMUS; TRIAMCINOLONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACNE; ADULT; ASEPTIC MENINGITIS; ATOPIC DERMATITIS; BURNING SENSATION; CARDIOTOXICITY; CATARACT; CHILD; CLINICAL TRIAL; CONTACT ALLERGY; CUSHING SYNDROME; CYTOPENIA; DERMATITIS; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DYSKINESIA; ENTEROCOLITIS; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GLAUCOMA; GRANULOMA; GROWTH RETARDATION; HEADACHE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTRICHOSIS; IMMEDIATE TYPE HYPERSENSITIVITY; INFANT; METABOLIC ACIDOSIS; METHEMOGLOBINEMIA; MYCOSIS; NAUSEA; NEUROTOXICITY; OPPORTUNISTIC INFECTION; PHOTOSENSITIVITY; PIGMENT DISORDER; PRURITUS; PYODERMA; RASH; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN ALLERGY; SKIN ATROPHY; SKIN INFLAMMATION; SKIN IRRITATION; SKIN NECROSIS; SKIN TUMOR; STRIA; TELANGIECTASIA; TORSADE DES POINTES; TREATMENT INDICATION; URTICARIA; VOMITING; XEROSIS; XEROSTOMIA;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ANTI-INFECTIVE AGENTS; CALCINEURIN; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; HISTAMINE H1 ANTAGONISTS; HUMANS;

VIOLA (ANGIOSPERM);

EID: 10344219981     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464230-00003     Document Type: Review

References (243)

1. Lilja G, Wickman M. Allergy - atopy - hypersensitivity: a matter of definition. Allergy 1998; 53 (11): 1011-2
2. Stoenescu M. 'Atopy', 'allergy' and 'hypersensitivity' are explicitly or implicitly defined in different ways. Allergy 1999; 54 (6): 640-2
3. Gerth van Wijk R, van Cauwenberge PB, Johansson SG. Revised terminology for allergies and related conditions [in Dutch]. Ned Tijdschr Geneeskd 2002 Nov 30; 146 (48): 2289-93
4. Hanifin JM. Atopiform dermatitits: do we need another confusing name for atopic dermatitis. Br J Dermatol 2002; 147: 430-2
5. Hanifin JM, Rayka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol 1980; 92: 44-7
6. Williams HC, Bourney PG, Hay RJ, et al. The UK Working Party's diagnostic criteria for atopic dermatitis. I: derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol 1994; 131 (3): 383-96
7. Diepgen TL, Sauerbrei W, Fartasch M. Development and validation of diagnostic scores for atopic dermatitis. J Clin Epidemiol 1996; 49 (9): 1031-8
8. Firooz A, Davoudi SM, Farahmand AN, et al. Validation of the diagnostic criteria for atopic dermatitis. Arch Dermatol 1999; 135: 514-6
9. European Task Force on Atopic Dermatitis Severity scoring of atopic dermatitis: the SCORAD index. Dermatology 1993; 186: 26-31
10. Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001; 10 (1): 11-8
11. Kay J, Gawkrodger DJ, Mortimer MJ, et al. The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol 1994 Jan; 30 (1): 35-9
12. Schultz Larsen F. Atopic dermatitis: an increasing problem. Pediatr Allergy Immunol 1996; 7 (9 Suppl.): 51-3
13. Schultz Larsen F, Diepgen T, Svensson A. The occurrence of atopic dermatitis in North Europe: an international questionnaire study. J Am Acad Dermatol 1996; 34: 760-4
14. Sugiura H, Umemoto N, Deguchi H. Prevalence of childhood and adolescent atopic dermatitis in a Japanese population: comparison with the disease frequency examined 20 years ago. Acta Derm Venereol 1998; 78: 293-4
15. Schäfer T, Dockery D, Kramer U, et al. Experiences with the severity scoring of atopic dermatitis in a population of German pre-school children. Br J Dermatol 1997; 137: 558-62
16. Williams HC. Epidemiology of atopic dermatitis. Clin Exp Dermatol 2000; 25 (7): 522-9
17. Leung DYM. Pathogenesis of atopic dermatitis. J Allergy Clin Immunol 1999; 104: S99-108
18. Wollenberg A, Bieber T. Atopic dermatitis: from the genes to skin lesions. Allergy 2000; 55: 205-13
19. Thepen T, Langeveld-Wildschut EG, Bihari IC, et al. A biphasic response against aeroallergen in atopic dermatitis showing a switch from an initial TH2 response to a TH1 response in situ: an immunocytochemical study. J Allergy Clin Immunol 1996; 97: 828-37
20. Kiekens RC, Thepen T, Oosting AJ, et al. Heterogeneity within tissue-specific macrophage and dendritic cell populations during cutaneous inflammation in atopic dermatitis. Br J Dermatol 2001; 145 (6): 957-65
21. Schleimer RP. Interactions between the hypothalamic-pituitary-adrenal axis and allergic inflammation. J Allergy Clin Immunol 2001; 106 (5 Suppl.): S270-4
22. Becker KG, Barnes KC. Underlying disease specificity of genetic loci in atopic dermatitis. J Invest Dermatol 2001; 117 (5): 1325-7
23. MacLean JA, Eidelman FJ. The genetics of atopy and atopic eczema. Arch Dermatol 2001; 137 (11): 1474-6
24. Weiss ST. Eat dirt: the hygiene hypothesis and allergic diseases. N Engl J Med 2002; 347 (12): 930-1
25. Schultz Larsen F. Atopic dermatitis: a genetic-epidemiologic study in a population-based twin sample. J Am Acad Dermatol 1993; 28 (5 Pt 1): 719-23
26. Williams HC. Is the prevalence of atopic dermatitis increasing? Clin Exp Dermatol 1992; 17 (6): 385-91
27. Wuthrich B, Schmid-Grendelmeier P. Natural course of AEDS. Allergy 2002; 57 (3): 267-8
28. Gil KM, Keefe FJ, Sampson HA, et al. The relation of stress and family environment to atopic dermatitis symptoms in children. J Am Acad Dermatol 1987; 30: 35-9
29. Strachan DP. Hay fever, hygiene, and household size. BMJ 1989; 299: 1259-60
30. Strachan DP. Allergy and family size: a riddle worth solving. Clin Exp Allergy 1997; 27: 235-6
31. McNally NJ, Williams HC, Phillips DR. Atopic eczema and home environment. Br J Dermatol 2002; 145: 730-6
32. Jarvis O, Chinn S, Luczynska C, et al. The association of family size with atopy and atopic diseases. Clin Exp Allergy 1997; 27: 240-5
33. Olesen AB, Ellingsen AR, Olesen H, et al. Atopic dermatitis and birth factors: historical follow up by record linkage. BMJ 1997; 314 (7086): 1003-8
34. Shaheen SO, Aaby P, Hall AJ. Measles and atopy in Guinea-Bissau. Lancet 1996; 347: 1792-6
35. Matricardi PM, Rosmini F, Riondino S. Exposure to foodborne and orofecal microbes versus airborne viruses in relation to atopy and allergic asthma: epidemiological study. BMJ 2000; 320: 412-7
36. Braun-Fahrländer C, Gassner M, Grize L, et al. Prevalence of hay fever and allergic sensitization in farmer's children and their peers living in the same rural community. Clin Exp Allergy 1999; 29: 28-34
37. Kilpelainen M, Terho EO, Helenius H, et al. Farm environment in childhood prevents the development of allergies. Clin Exp Allergy 2000; 30: 201-8
38. Harris JM, Cullinan P, Williams HC, et al. Environmental associations with eczema in early life. Br J Dermatol 2001; 144 (4): 795-802
39. Braun-Fahrländer C, Riedler J, Herz U, et al. Environmental exposure to endotoxin and its relation to asthma in school-age children: Allergy and Endotoxin Study Team. N Engl J Med 2002; 347 (12): 930-1
40. Lauener RP, Birchler T, Adamski J, et al. Expression of CD14 and Toll-like receptor 2 in farmers' and non-farmers' children: ALEX Study Group. Lancet 2002; 360 (9331): 465-6
41. Kalliomäki M, Isolauri E. Role of intestinal flora in the development of allergy. Curr Opin Allergy Clin Immunol 2003; 3 (1): 15-20
42. Kalliomäki M, Salminen S, Arvilommi H, et al. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001; 357: 1076-9
43. Ehlers I, Worm M, Sterry W, et al. Sugar is not an aggravating factor in atopic dermatitis. Acta Derm Venerol 2001; 81: 282-4
44. Yazdanbakhsh M, Kremsner PG, van Ree R. Allergy, parasites, and the hygiene hypothesis. Science 2002; 296 (5567): 490-4
45. Zesch A. Externa. Berlin: Springer, 1988
46. Goodyear HM, Spowart K, Harper JI. 'Wet-wrap' dressings for the treatment of atopic eczema in children [letter]. Br J Dermatol 1991; 125: 604
47. Mallon E, Powell S, Bridgemann A. 'Wet-wrap' dressings for the treatment of atopic eczema in the community. J Dermatol Treat 1994; 5: 97-8
48. Donald S. Know how: wet wraps in atopic eczema. Nurs Times 1997; 93 (44): 67-8
49. Gloor M, Thoma K, Fluhr J. Dermatologische Externatherapie. Berlin: Springer, 2000: 321-3
50. Gloor M, Haus C, Fluhr J, et al. Do shake lotions, zinc oil and polyethylene glycol gels produce dehydration or moisturization? Skin Pharmacol Appl Skin Physiol 2001; 14 (1): 34-43
51. Loden M, Andersson AC, Lindberg M. Improvement in skin barrier function in patients with atopic dermatitis after treatment with a moisturizing cream (Canoderm). Br J Dermatol 1999; 140: 264-7
52. Loden M, Andersson AC, Andersson C, et al. Instrumental and dermatologist evaluation of the effect of glycerine and urea on dry skin in atopic dermatitis. Skin Res Technol 2001; 7: 209-13
53. Long CC, Finlay AY. The finger-tip unit: a new practical measure. Clin Exp Dermatol 1991; 16: 444-7
54. Ehlers A, Stangier U, Gieler U. Treatment of atopic dermatitis: a comparison of psychological and dermatological approaches to relapse prevention. J Consult Clin Psychol 1995; 63: 624-35
55. Hurwitz S. Clinical pediatric dermatology. 2nd ed. Philadelphia (PA): WB Saunders Co., 1993
56. Maibach HI. In vivo percutaneous penetration of corticosteroids in man and unresolved problems in their efficacy. Dermatologica 1976; 152 Suppl. 1: 11-25
57. Hepburn DJ, Aeling JL, Weston WL. A reappraisal of topical steroid potency. Pediatr Dermatol 1996; 13 (3): 239-45
58. Hill CJ, Rostenberg Jr A. Adverse effects from topical steroids. Cutis 1978; 21: 624-8
59. Queille C, Pommarede R, Saurat JH. Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis of childhood. Pediatr Dermatol 1984; 1: 246-53
60. McLean C, Lobo R, Brazier D. Cataracts, glaucoma, femoral avascular necrosis caused by topical steroids in the treatment of atopic dermatitis of childhood [letter]. Pediatr Dermatol 1995; 346: 1298
61. Charman C. Clinical evidence: atopic eczema. BMJ 1999 Jun 12; 318 (7198): 1600-4
62. Niedner R. Kortikoide in der Dermatologie. Bremen: Unimed Verlag, 1998: 65-7
63. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic dermatitis. Health Technol Assess 2000; 4 (37): 1-191
64. Menday AP, Noble WC. Topical betamethasone/fusidic acid in eczema: efficacy against and emergence of resistance in Staphylococcus aureus. J Dermatol Treat 2000; 11: 143-9
65. Furue M, Terao H, Rikihisa W, et al. Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis. Br J Dermatol 2003; 148 (1): 128-33
66. Bleehen SS, Chu AC, Hamann I, et al. Fluticasone propionate 0.05% cream in the treatment of atopic eczema: a multicentre study comparing once-daily treatment and once-daily vehicle cream application versus twice-daily treatment. Br J Dermatol 1995; 133 (4): 592-7
67. Koopmans B, Lasthein-Andersen B, Mork NJ, et al. Multicentre randomized double-blind study of locoid lipocream fatty cream twice daily versus locoid lipocream once daily and locobase once daily. J Dermatol Treat 1995; 6 (2): 103-6
68. Sudilovsky A, Muir JG, Bocobo FC. A comparison of single and multiple applications of halcinonide cream. Int J Dermatol 1981; 20 (9): 609-13
69. Lagos BR, Maibach HI. Frequency of application of topical corticosteroids: an overview. Br J Dermatol 1998; 139 (5): 763-6
70. van der Meer JB, Glazenburg EJ, Mulder PG, et al. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate: The Netherlands Adult Atopic Dermatitis Study Group. Br J Dermatol 1999 Jun; 140 (6): 1114-21
71. Williams HC. Do topical steroids reduce relapses in adults with atopic dermatitis? Arch Dermatol 1999; 135: 1530-1
72. Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002; 147 (3): 582-37
73. Hjorth N, Schmidt H, Thomsen K. Fusidic acid plus betamethasone in infected or potentially infected eczema. Pharmatherapeutica 1985; 4 (2): 126-31
74. Ramsay CA, Savoie JM, Gilbert M, et al. The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate. J Eur Acad Dermatol Venerol 1996; 7 Suppl. 1: 5-22
75. Wachs GN, Maibach HI. Co-operative double-blind trial of an antibiotic/corticoid combination in impetiginized atopic dermatitis. Br J Dermatol 1976 Sep; 95 (3): 323-8
76. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13: 136-42
77. Anjana R. NF-Atp: a transcription factor required for the coordinate induction of several cytokine genes. Immunol Today 1994; 15: 274-81
78. Wollenberg A, Regele D, Sharma S, et al. Topical tacrolismus (FK506) treatment leads to profound alterations of the antigen presenting cells in lesional atopic dermatitis skin [abstract]. J Invest Dermatol 1996; 107: 468
79. Hisatoma A, Mitamura T, Kumura M, et al. Comparison of FK506 (tacrolimus) and glucocorticoid ointment on dermal atrophogenicity in rats. J Toxicol Pathol 1997; 10: 97-102
80. Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 1998; 111 (3): 396-8
81. Reinhard T, Reis A, Mayweg S, et al. Topical Fk506 in inflammatory corneal and conjunctival diseases: a pilot study. Klin Monatsbl Augenheilkd 2002; 219 (3): 125-31
82. Menni S, Boccardi D, Rigoni C. Hypertrichosis in a kidney-transplanted child: dramatic regression after cyclosporin A was replaced by FK506. J Dermatol Treat 1999; 10: 59-61
83. Lauerma AI, Surber C, Maibach HI. Absorption of topical tacrolimus (FK506) in vitro through human skin: comparison with cyclosporin A. Skin Pharmacol 1997; 10: 230-4
84. Nakagawa H, Etoh T, Ishibashi Y, et al. Tacrolimus ointment for atopic dermatitis [letter]. Lancet 1994; 344: 883
85. Alaiti S, Kang S, Fiedler VC, et al. Tacrolimus (FK506) ointment for atopic dermatitis: a phase 1 study in adults and children. J Am Acad Dermatol 1998; 38: 69-76
86. Ruzicka T, Bieber T, Schopf E, et al. A short term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 1997; 337: 816-21
87. Boguniewicz M, Fiedler VC, Raimer S, et al. A randomised, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. J Allergy Clin Immunol 1998; 102: 637-44
88. Hanifin J. Use of tacrolimus ointment in 3-6 year olds with atopic dermatitis (AD); dose-escalation study [letter]. The Tacrolimus Ointment Study Group. J Invest Dermatol 1998; 110: 681
89. Paller A, Eichenfield LF, Leung DYM, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in children: the Tacrolimus Ointment Study Group. J Am Acad Dermatol 2001; 44 (1): 47-57
90. Kang S, Lucky A, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children: the Tacrolimus Ointment Study Group. J Am Acad Dermatol 2001; 44: S58-64
91. Cheer SM, Plosker GL. Tacrolimus ointment: a review of its therapeutic potential as a topical therapy in atopic dermatitis. Am J Clin Dermatol 2001; 2 (6): 389-406
92. Remitz A, Kyllonen H, Granlund H, et al. Reduction of staphylococcal colonization of skin in atopic dermatitis with 0,1% tacrolimus ointment therapy. J Allergy Clin Immunol 2001; 107: 196-7
93. Pournaras CC, Lubbe J, Saurat JH. Staphylococcal colonization in atopic dermatitis treatment with topical tacrolimus (Fk506). J Invest Dermatol 2001; 116 (3): 480-1
94. Lauerma AI, Maibach HI, Granlund H, et al. Inhibition of contact allergy reactions by topical FK506 [letter]. Lancet 1992; 340: 556
95. Nakagawa H, Etoh T, Yokota Y, et al. Tacrolimus has antifungal activities against Malassezia furfur isolated from healthy adults and patients with atopic dermatitis. Clin Drug Invest 1996; 12: 244-50
96. Faergemann J, Jones JC, Hettler O, et al. Pityrosporum ovale (Malassezia furfur) as the causative agent of seborrheic dermatitis: new treatment options. Br J Dermatol 1996; 134 Suppl. 46: 12-5
97. Grassberger M, Baumrucker T, Enz A, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999; 141: 24-73
98. Meingassner JG, Grassberger M, Fahrngruber H, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 1997 Oct; 137 (4): 568-76
99. Hultsch T, Muller KD, Meingassner JG, et al. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin- dependent manner. Arch Dermatol Res 1998; 290: 501-7
100. Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981): preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 2001; 20 (4): 233-41
101. Wellington K, Jarvis B. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis. Drugs 2002; 62 (5): 817-40
102. Schopf RE. Pimecrolimus: Novartis. Curr Opin Investig Drugs 2002; 3 (5): 720-4
103. Mrowitz U, Graeber M, Brautigam M, et al. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 1998; 139: 992-6
104. Quille-Roussel C, Graeber M, Thurston M, et al. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Dermatitis 2000; 42 (6): 349-50
105. Van Leent EJM, Graber M, Thurston M, et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998; 134: 805-9
106. Van Leent EJM, Graeber M, Hedgecock S, et al. SDZ ASM 981: an emerging new standard for the treatment of atopic dermatitis [abstract]. J Eur Acad Dermatol Venereol 1998; 12 (2): S198
107. Morris A, Cardno M, Burtin P, et al. Low systemic SDZ ASM 981 exposure in children 5-16 years old treated with the 1% cream for their atopic dermatitis [abstract]. J Eur Acad Dermatol Venereol 1999; 12 Suppl. 2: S160
108. Harper J, Green A, Scott E, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 2001; 144 (4): 781-7
109. Luger T, Van Leent EJ, Graeber M, et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001; 144 (4): 788-94
110. Meurer M, Folster-Holst R, Wozel G, et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002; 205 (3): 271-7
111. Rycroft RJG. Principal irritants and sensitizers. In: Champion RH, Burton JL, Burns DA, et al., editors. Textbook of dermatology. 6th ed. Oxford: Blackwell Science, 1998
112. Freitag G, Hoppner T. Results of a postmarketing drug monitoring survey with a polidocanol-urea preparation for dry, itching skin. Curr Med Res Opin 1997; 13 (9): 529-37
113. Drake LA, Cohen L, Gillies R, et al. Pharmacokinetics of doxepin in subjects with pruritic atopic dermatitis. J Am Acad Dermatol 1999; 41 (2 Pt 1): 209-14
114. Breneman DL, Dunlap FE, Monroe EW, et al. Doxepin releaves eczema-associated pruritus within 15 minutes and is not accompanied by a risk of rebound upon discontinuation. J Dermatol Treat 1997; 8 (3): 161-8
115. Berberian BJ, Breneman DL, Drake LA, et al. The addition of topical doxepin to corticosteroid therapy: an improved treatment regimen for atopic dermatitis. Int J Dermatol 1999; 38 (2): 145-8
116. Drake LA, Millikan LE. The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis: Doxepin Study Group. Arch Dermatol 1995; 131 (12): 1403-8
117. Weisshaar E, Heyer G, Forster C, et al. Effect of topical capsaicin on the cutaneous reactions and itching to histamine in atopic eczema compared to healthy skin. Arch Dermatol Res 1998; 290 (6): 306-11
118. Reimann S, Luger T, Metze D. Topische Anwendung von Capsaicin in der Dermatologie zur Therapie von Juckreiz und Schmerz. Hautarzt 2000; 51: 164-72
119. Hagermark O, Wahlgren CF. Treatment of itch. Semin Dermatol 1995; 14 (4): 320-5
120. Simons FE. Comparative pharmacology of H (1) antihistamines: clinical relevance. Am J Med 2002; 113 Suppl. 8: 38-46
121. Roos TC, Merk HF. Important drug interactions in dermatology. Drugs 2000; 59 (2): 181-92
122. Woosley RL. Cardiac action of antihistamines. Annu Rev Pharmacol Toxicol 1996; 36: 233-52
123. Kreutner W, Hey JA, Chiu P, et al. Preclinical pharmacology of desloratadin, a selective and nonsedating histamine h1 receptor antagonist. 2nd communication: lack of central nervous system and cardiovascular effects. Arzneimittelforschung 2000; 50: 441-8
124. Mazzotta P, Loebstein R, Koren G. Treating allergic rhinitis in pregnancy: safety considerations. Drug Saf 1999; 20 (4): 361-75
125. Paris-Kohler A, Megret-Gabeaud ML, Fabre C, et al. The allergic pregnant woman. Allerg Immunol (Paris) 2001; 33 (10): 399-403
126. Spencer JP, Gonzalez III LS, Barnhart DJ. Medications in the breast-feeding mother. Am Fam Physician 2001 Jul 1; 64 (1): 119-26
127. McHenry PM, Williams HC, Bingham EA. Management of atopic eczema: Joint Workshop of the British Association of Dermatologists and the Research Unit of the Royal College of Physicians of London. BMJ 1995 Apr 1; 310 (6983): 843-7
128. Rukwied R, Lischetzki G, McGline F, et al. Mast cell mediators other than histamine induce pruritus in atopic dermatitis patients: a dermal microdialysis study. Br J Dermatol 2000; 142 (6): 1114-20
129. Savin JA, Paterson WD, Adam K, et al. Effects of trimeprazine and trimipramine on nocturnal scratching in patients with atopic eczema. Arch Dermatol 1979; 115 (3): 313-5
130. Foulds IS, MacKie RM. A double-blind trial of the H2 receptor antagonist cimetidine, and the H1 receptor antagonist promethazine hydrochloride in the treatment of atopic dermatitis. Clin Allergy 1981; 11 (4): 319-23
131. Frosch PJ, Schwanitz HJ, Macher E. A double blind trial of H1 and H2 receptor antagonists in the treatment of atopic dermatitis. Arch Dermatol Res 1984; 276 (1): 36-40
132. Monroe EW, Bernstein DI, Fox RW, et al. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria. Arzneimittelforschung 1992; 42 (9): 1119-21
133. Klein PA, Clark RA. An evidence based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol 1999; 135 (12): 1522-5
134. Hannuksela M, Kalimo K, Lammintausta K, et al. Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults. Ann Allergy 1993 Feb; 70 (2): 127-33
135. Henz BM, Metzenauer P, O'Keefe E, et al. Differential effects of new-generation H1-receptor antagonists in pruritic dermatoses. Allergy 1998 Feb; 53 (2): 180-3
136. Hjorth N. Terfenadine in the treatment of chronic idiopathic urticaria and atopic dermatitis. Cutis 1988 Oct 27; 42 (4A): 29-30
137. Doherty V, Sylvester DG, Kennedy CT, et al. Treatment of itching in atopic eczema with antihistamines with a low sedative profile. BMJ 1989 Jan 14; 298 (6666): 96
138. Langeland T, Fagertun HE, Larsen S. Therapeutic effect of loratadine on pruritus in patients with atopic dermatitis: a multi-crossover-designed study. Allergy 1994; 49 (1): 22-6
139. Patel P, Gratton D, Eckstein G, et al. A double-blind study of loratadine and cetiricine in atopic dermatitis. J Dermatol Treat 1997; 8(4): 249-53
140. Klein GL, Galant SP. A comparison of the antipruritic efficacy of hydroxyzine and cyproheptadine in children with atopic dermatitis. Ann Allergy 1980; 44 (3): 142-5
141. Simons R, Estelle F, Simons KJ, et al. Pharmacokinetics and antipruritic effects of hydroxicine in children with atopic dermatitis. J Pediatr 1984; 104 (1): 123-7
142. Berth-Jones J, Graham-Brown RA. Failure of terfenadine in relieving the pruritus of atopic dermatitis. Br J Dermatol 1989; 121 (5): 635-7
143. Wahlgren CF, Hagermark O, Bergstrom R. The antipruritic effect of a sedative and a non-sedative antihistamine in atopic dermatitis. Br J Dermatol 1990; 122 (4): 545-51
144. Eysenbach G, Williams H, Diepgen TL. Antihistamines for atopic eczema (Protocol for a Cochrane Review). Available in the Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 3. Oxford: Update Software, 2000
145. Veien NK, Kaaber K, Larsen PO, et al. Ranitidine treatment of hand eczema in patients with atopic dermatitis: a double-blind, placebo-controlled trial. J Am Acad Dermatol 1995; 32 (6): 1056-7
146. Kagi MK. Leukotriene receptor antagonists: a novel therapeutic approach in atopic dermatitis? Dermatology 2001; 203 (4): 280-3
147. Carruci JA, Washenik K, Weinstein A, et al. The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis. Arch Dermatol 1998; 134: 785-6
148. Woodmansee DP, Simon RA. A pilot study of zileuton in atopic dermatitis. Ann Allergy 1999; 83: 584-52
149. Capella GL, Grigerio E, Altomare G. A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults. Eur J Dermatol 2001; 11 (3): 209-13
150. Yanase DJ, David-Bajar K. The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis. J Am Acad Dermatol 2001; 44 (1): 89-93
151. Pei AY, Chan HH, Leung TF. Montelukast in the treatment of children with moderate-to-severe atopic dermatitis: a pilot study. Pediatr Allergy Immunol 2001; 12 (3): 154-8
152. Benton EC, McFarlane HA, Barnetson RS. Trial of nedocromil sodium in atopic eczema. Br J Dermatol 1990 Jun; 122 (6): 817-20
153. Benton EC, McFarlane HA, Barnetson RS. Trial of nedocromil sodium in atopic eczema. Br J Dermatol 1990; 122 (6): 817-20
154. Van Bever HP, Stevens WJ. Nedocromil sodium cream in the treatment of atopic dermatitis [letter]. Eur J Pediatr 1989; 149 (1): 74
155. Ahluwalia P, McGill JI, Church MK. Nedocromil sodium inhibits histamine-induced itch and flare in human skin. Br J Pharmacol 2001; 132 (3): 613-6
156. Kimata H. Selective enhancement of production of IgE, IgG4, and Th2-cell-cytokine during the rebound phenomenon in atopic dermatitis and prevention by suplastate tosilate. Ann Allergy Asthma Immunol 1999; 82 (3): 293-5
157. Schmelz M, Schmidt R, Bickel A, et al. Specific C-receptors for itch in human skin. J Neurosci 1997; 17: 8003-8
158. Bernstein JE, Grinzi RA. Butorphanol-induced pruritus antagonized by naloxone. J Am Acad Dermatol 1981; 5: 227-8
159. Metze D, Reimann S, Beissert S, et al. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J Am Acad Dermatol 1981; 134: 785-6
160. Galli E, Chini L, Moschese V, et al. Methylprednisolone bolus: a novel therapy for severe atopic dermatitis. Acta Paediatr 1994; 83 (3): 315-7
161. Aylett SE, Atherton DJ, Preece MA. The treatment of difficult atopic dermatitis in childhood with oral beclomethasone dipropionate. Acta Derm Venereol Suppl (Stockh) 1992; 176: 123-5
162. De Rie MA, Meinardi MMHM, Bos JD. Lack of efficacy of topical cyclosporin A atopic dermatitis and allergic contact dermatitis. Acta Derm Venereol 1991; 71: 452-4
163. de Prost Y, Teillac D, Paquez F, et al. Placebo-controlled trial of topical cyclosporin in severe alopecia areata. Lancet 1986 Oct 4; 2 (8510): 803-4
164. de Prost Y, Bodemer C, Teillac D. Randomised double-blind placebo-controlled trial of local cyclosporin in atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1989; 144: 136-8
165. Camp RD, Reitamo S, Friedmann PS, et al. Cyclosporin A in severe, therapy-resistant atopic dermatitis: report of an international workshop, April 1993. Br J Dermatol 1993 Aug; 129 (2): 217-20
166. Granlund H, Erkko P, Sinisalo M, et al. Cyclosporin in atopic dermatitis: time to relapse and effect of intermittent therapy. Br J Dermatol 1995; 132 (1): 106-12
167. Zaki I, Emerson R, Allen BR. Treatment of severe atopic dermatitis in childhood with cyclosporin. Br J Dermatol 1996; 135 Suppl. 48: 21-4
168. Harper JI, Ahmed I, Barclay G, et al. Cyclosporine for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol 2000; 142: 52-8
169. van Joost T, Heule F, Korstanje M, et al. Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study. Br J Dermatol 1994; 130 (5): 634-40
170. Wahlgren CF. Itch and atopic dermatitis: clinical and experimental studies. Acta Derm Venereol Suppl (Stockh) 1991; 165: 1-53
171. Sowden JM, Berth-Jones J, Ross JS, et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 1991 Jul 20; 338 (8760): 137-40
172. Munro CS, Higgins EM, Marks JM, et al. Cyclosporin A in atopic dermatitis: therapeutic response is dissociated from effects on allergic reactions. Br J Dermatol 1991; 124 (1): 43-8
173. Munro CS, Levell NJ, Shuster S, et al. Maintenance treatment with cyclosporin in atopic eczema. Br J Dermatol 1994; 130 (3): 376-80
174. Berth-Jones J, Finlay AY, Zaki I, et al. Cyclosporine in severe childhood atopic dermatitis: a multicenter study. J Am Acad Dermatol 1996; 34: 1016-21
175. Zurbriggen B, Wuthrich B, Cachelin AB, et al. Comparison of two formulations of cyclosporin A in the treatment of severe atopic dermatitis: a double-blind, single-centre, cross-over pilot study. Dermatology 1999; 198 (1): 56-60
176. Bunikowski R, Gerhold K, Brautigam M, et al. Effect of low-dose cyclosporin a microemulsion on disease severity, interleukin-6, interleukin-8 and tumor necrosis factor alpha production in severe pediatric atopic dermatitis. Int Arch Allergy Immunol 2001; 125 (4): 344-8
177. Sepp N, Fritsch PO. Can cyclosporin A induce permanent remission of atopic dermatitis? Br J Dermatol 1998; 128 (2): 213-6
178. Berth-Jones J, Takwale A, Tan E, et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol 2002; 147 (2): 324-30
179. Meggitt SJ, Reynolds NJ. Azathioprine for atopic dermatitis. Clin Exp Dermatol 2001; 26: 369-75
180. Snow J, Gibson L. A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatology patients. J Am Acad Dermatol 1995; 32: 114-6
181. Sidbury R, Hanifin JM. Systemic therapy of atopic dermatitis. Clin Exp Dermatol 2000; 25 (7): 559-66
182. Knowles WR, Chernosky ME. Pitryiasis rubra pilaris-prolonged treatment with methotrexate. Arch Dermatol 1970; 102: 603-12
183. Silverman T, Kitchen JE, Pomerantz ML, et al. Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. J Am Acad Dermatol 1997; 37: 445-9
184. Nousari HC, Sragovich A, Kimyai-Asadi A, et al. Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J Am Acad Dermatol 1999; 40: 265-8
185. Picknacker A, Luger TA, Schwarz T. Dyshidrotic eczema treated with mycophenolate mofetil. Arch Dermatol 1998; 134: 378-9
186. Epinette WW, Parker CM, Jones EL, et al. Mycophenolic acid for psoriasis: a review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol 1987; 17 (6): 962-71
187. Alomar A, Gimenez-Camarasa JM, de Moragas JM. The use of levamisole in atopic dermatitis: a prospective study. Arch Dermatol 1987; 114 (9): 1316-9
188. White CR, Hanifin JM. Levamisole therapy in atopic dermatitis: randomized double-blind evaluation. Arch Dermatol 1978; 114 (9): 1314-5
189. Grandel KE, Farr RS, Wanderer AA, et al. Association of platelet-activating factor with primary acquired cold urticaria. N Engl J Med 1985 Aug 15; 313 (7): 405-9
190. Abeck D, Andersson T, Grosshans E, et al. Topical application of a platelet-activating factor (PAF) antagonist in atopic dermatitis. Acta Derm Venereol 1997; 77 (6): 449-51
191. Edward S, Schulman AM. Development of a monoclonal anti-immunoglobulin e antibody (omalizumab) for the treatment of allergic respiratory disorders. J Respir Crit Care Med 2001; 164: S6-S11
192. Hamid Q, Boguniewicz M, Leung DY. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest 1994; 94 (2): 870-6
193. Boguniewicz M, Jaffe HS, Izu A, et al. Recombinant gamma interferon in treatment of patients with atopic dermatitis and elevated IgE levels. Am J Med 1990; 88 (4): 365-70
194. Hanifin JM, Schneider LC, Leung DY, et al. Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol 1993; 28 (2 Pt 1): 189-97
195. Hanifin JM, Chan S. Biochemical and immunologic mechanisms in atopic dermatitis: new targets for emerging therapies. J Am Acad Dermatol 1997; 41: 72-7
196. Stevens SR, Hanifin JM, Hamilton T, et al. Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels. Arch Dermatol 1998; 134: 799-804
197. Schneider LC, Baz Z, Zarcone C, et al. Longterm therapy with recombinant interferon-gamma for atopic dermatitis. Ann Allergy Asthma Immunol 1998; 80: 263-8
198. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD 95 with human intravenous immunoglobulin. Science 1998; 282: 490-3
199. Pons-Guiraud A. Value of allerglobulin in the treatment of atopic dermatitis in children and young adults: a double-blind randomized study. Rev Med Interne 1986; 7 (5): 537-42
200. Nydegger UE, Sturzenegger M. Adverse effects of intravenous immunoglobulin therapy. Drug Saf 1999; 21: 171-85
201. Grewe S, Chan SC, Hanifin JM. Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness. J Allergy Clin Immunol 1982; 70: 452-7
202. Epstein E. Theophylline ethylenediamine as an antipruritic agent. Arch Dermatol Syph 1946; 53: 281-4
203. Butler JM, Chan SC, Stevens SR, et al. Increased leukocyte histamine release with elevated cyclic AMP-phosphodiesterase. J Allergy Clin Immunol 1983; 71: 490-7
204. Cooper KD, Kang KF, Chan SC, et al. Phosphodiesterase inhibition by Ro 20-1724 reduces hyper-IgE synthesis by atopic dermatitis cells in vitro. J Invest Dermatol 1985; 84: 477-82
205. Hanifin JM, Chan SC, Cheng JB. Type 4 phosphodiesterase inhibitors have clinical and in vivo anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 1996; 107: 51-6
206. Griffiths CEM, van Leent EJM, Gilbert M, et al. Randomized comparison of the type-4-phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis: Cipamfylline Study Group. Br J Dermatol 2002; 147 (2): 299-307
207. Christensen SB, Guider A, Forster CJ. 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosphodiesterase-4 for the treatment of asthma. J Med Chem 1998; 41: 821-35
208. Griswold DE, Webb EF, Badger EM. SB 207499 (Ariflo), a second generation phosphodiesterase-4-inhibitor reduces tumor necrosis factor alpha and interleukin-4 production in vivo. J Pharmacol Exp Ther 1998; 287: 705-11
209. Houslay MD, Sullivan M, Bolger GB. The multienzyme PDE4 cyclic adenosine monophosphate-specific family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Adv Pharmacol 1998; 44: 225-342
210. Weinberg E, Fourie B, Allmann B, et al. The use of cefadroxil in superinfected atopic dermatitis. Curr Ther Res Clin Exp 1992; 52 (2): 671-6
211. Ewing CI, Ashcroft C, Gibbs ACC, et al. Flucloxacillin in the treatment of atopic dermatitis. Br J Dermatol 1998; 138; 1022-9
212. Salo OP, Gordin A, Brandt H, et al. Efficacy and tolerability of erythromycin acistrate and erythromycin stearate in acute skin infections of patients with atopic eczema. J Antimicrob Chemother 1988; 21 Suppl. D: 101-6
213. Boguniewicz M, Sampson H, Leung SB, et al. Effects of cefuroxime acetil an Staphylococcus aureus colonization and superantigen production in atopic dermatitis. J Allergy Clin Immunol 2001; 108 (4): 651-2
214. Breuer K, Haussler S, Kapp A, et al. Staphylococcus aureus: colonizing features and influence of an anti-bacterial treatment in adults with atopic dermatitis. Br J Dermatol 2002; 147 (1): 55-61
215. Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of asthma: a meta-analysis of prospective, randomized, double-blind, placebo-controlled studies. Clin Ther 2000; 22: 329-41
216. Malling HJ, Abreu-Nogueira J, Alvarez-Cuesta E. EAACI/ESPACI position paper on local immonotherapy. Allergy 1998; 53: 833-44
217. EAACI Immunotherapy Subcommittee. Immunotherapy postion paper. Allergy 1993; 48 Suppl. 14: 9-35
218. Mailing HJ. Immunotherapy as an effective tool in allergy treatment. Allergy 1998; 53: 461-72
219. Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: an analysis of randomised, prospective single- or double-blind, placebo-contolled studies. Clin Ther 2000; 22: 342-50
220. Djurup R, Österballe O. IgG subclass antibody response in grass pollen allergic patients undergoing specific immunotherapy: prognostic value of serum IgG subclass antibody levels early in immunotherapy. Allergy 1984; 39: 433-41
221. Durham SR, Till SJ. Immunologic changes associated with allergen immunotherapy. Allergy Clin Immunol 1998; 102: 157-64
222. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341: 468-75
223. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic desaeses: a WHO position paper. J Allergy Clin Immunol 1998; 102 (4 Pt 1): 558-62
224. Beck LA, Leung DY. Allergen sensitization through the skin induces systemic allergic responses. J Allergy Clin Immunol 2000; 106 (5 Suppl.): S258-63
225. Mastrandrea F. Immunotherapy in atopic dermatitis. Expert Opin Investig Drugs 2001; 10 (1): 49-63
226. Secrist H, Chelen CJ, Wen Y, et al. Allergen immunotherapy decreases interleukin-4 production in CD4+ T-cells from allergic individuals. J Exp Med 1993; 178: 2123-30
227. Jutel M, Pichler WJ, Skrbic D, et al. Bee venom immunotherapy results in decrease in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen stimulated T cell cultures. J Immunol 1995; 154: 4178-94
228. Bellinghausen I, Metz G, Enk AH, et al. Insect venom immunotherapy induces intereukin-10 production and a Th2-to Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol 1997; 27: 1131-9
229. Müller UR, Akdis CA, Fricker M, et al. Succesful immunotherapy with T cell epitope peptides of bee venom phospholipase A2 induces specific T cell anergy in bee sting allergic patients. J Allergy Clin Immmol 1998; 101: 747-54
230. Akdis CA, Blesken T, Akdis M, et al. Role of IL-10 in specific immunotherapy. J Clin Invest 1998; 102: 98-106
231. Schandene L, Alonso-Vega C, Willems F, et al. B7/CD 28 dependent IL-5 production by human resting T cells inhibited by IL-10. J Immunol 1994; 152: 4368-74
232. Akdis CA, Blasé K. IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy. FASEB J 1999; 13: 603-9
233. Kaufman HS, Roth HL. Hyposensitization with aluminium preciptated extracts in atopic dermatitis-a placebo-controlled study. Ann Allergy 1974; 32 (6): 321-30
234. Warner JO, Soothill JF, Hey EN. Controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with asthma. Lancet 1978; II: 912-7
235. Glover MT, Atherton DJ. A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Exp Allergy 1992; 22: 440-6
236. Kojima T, Akiyama H, Sasai M, et al. Anti-allergic effect of apple polyphenols on patients with atopic dermatitis: a pilot study. Allergol Int 2000; 49: 69-73
237. Pessi T, Sütas Y, Hurme M, et al. Interleukin-10 generation in atopic children following oral Lactobacillus rhamnosus GG. Clin Exp Allergy 2000; 30 (12): 1804-8
238. Frotscher B, Anton K, Worm M. Inhibition of IgE production by the imidazoquinoline resiquimod in nonallergic and allergic donors. J Invest Dermatol 2002; 119 (5): 1059-64
239. Aleksza M, Lukázs A, Antal-Szalmás P, et al. Increased frequency of intracellular interleukin (IL)-13 and IL-10, but not IL-4, expressing CD+ and CD8+ peripheral T cells of patients with atopic dermatitis. Br J Dermatol 2002; 147 (6): 1135-41
240. Gallo RL, Murakami M, Ohtake T, et al. Biology and clinical relevance of naturally occurring antimicrobial peptides. J Allergy Clin Immunol 2002; 110 (6): 823-31
241. Marchini G, Lindow S, Brismar H, et al. The newborn infant is protected by an innate antimicrobial barrier: peptide antibiotics are present in the skin and the vernix caseosa. Br J Dermatol 2002; 147 (6): 1127-34
242. Shiradawa T, Enomoto T, Shimazu S, et al. The inverse association between tuberculin responses and atopic disorder. Science 1997; 275: 77-9
243. Janssen R, Kruisselbrink A, Hoogteijling L, et al. Analysis of recombinant amycobacteria as T helper type 1 vaccines in an allergy challenge model. Immunology 2001; 102 (4): 441-9